PMEF
FHTX icon

Point72 Middle East FZE’s Foghorn Therapeutics FHTX Stock Holding History

Point72 Middle East FZE’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37
Closed -$236 – 1812
2022
Q4 		$236 Buy
+37
New +$279 ﹤0.01% 1846

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Middle East FZE's FHTX Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Foghorn Therapeutics (FHTX) in Q1 2023, closing a stake of 37 shares — an estimated $236 sold.

Point72 Middle East FZE first reported a position in FHTX in Q4 2022 and held it in 1 quarter. The position peaked at $236 in Q4 2022. 60 funds tracked by Wall St. Rank hold FHTX as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Foghorn Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 37 Foghorn Therapeutics shares in Q1 2023, an estimated $236.
  • Point72 Middle East FZE first reported a position in Foghorn Therapeutics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Foghorn Therapeutics position peaked at $236 in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.